Stem cells have become the corner stone of research into providing revolutionary treatments for dry macular degeneration. Continuing its Phase I & Phase II clinical trials, StemCells Inc has transplanted stem cells into its first patient suffering from dry macular degeneration.
Macular degeneration is an eye disease more common among people aged 50 and older. According to the National Institute of Health, it is the leading cause of blindness in older adults.
Dry macular degeneration occurs when deposits of drusen form in the eye, impacting the central vision of the patients. It is a slow and progressive eye disease that has no significant treatment. Wet macular degeneration is the more severe form of the disease and results from blood vessels that leak blood into the retina, causing a much more rapid vision loss.
This round of stem cell research for macular degeneration was given to StemCells Inc by the FDA in February.